INmune Bio, Inc. Announces First Patient Treated with NK Cell Priming “Pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)

INmune Bio, Inc. announced that the first patient has been treated in the company’s Phase I clinical trial of its Natural Killer cell priming platform, INKmune, as a potential treatment for high-risk myelodysplastic syndrome.